Table 1.
Baseline characteristics of the study subjects
| PDAC patients (n=165) | Controls (n=151) | |
|---|---|---|
| Sex (M/F) (%) | 70 (42.4%)/95 (57.6%) | 85 (56.3%)/66 (43.7%) |
| Age, mean (SD), years* | 63.62 (12.49) | 47.74 (14.74) |
| CA19-9, mean (SD), U/ml* | 4330.5 (8980.90) | 15.82 (21.38) |
| sEV-EZR, mean (SD), pg/ml* | 32.43 (20.78) | 21.88 (11.43) |
| sEV count, mean (SD), Cal. Conc. (particles/ml plasma) | 2.34E+12 (2.40E+12) | 2.20E+12 (2.34E+12) |
| sEV particle size | ||
| Mean size, mean (SD), nm* | 90.92 (18.43) | 80.057 (8.25) |
| Mode size, mean (SD), nm* | 70.38 (10.96) | 63.63 (6.98) |
| TNM stage (%) | ||
| I-II | 49 (29.7%) | |
| III-IV | 116 (70.3%) | |
| Overall survival, median (SD), months | 7.96 (15.20) | |
| TNM stages I-II | 15.75 (20.47) | |
| TNM stages III-IV** | 5.28 (10.54) |
*
P<.0001 between PDAC patients and high-risk controls.
**
P<.0001 between stages I-II and stages III-IV PDAC patients.
PDAC, pancreatic ductal adenocarcinoma; M, male; F, female.